within Pharmacolibrary.Drugs.ATC.N;

model N05BA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.89,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 0.015,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0014166666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Potassium clorazepate is a benzodiazepine prodrug used primarily as an anxiolytic, anticonvulsant, and for the management of alcohol withdrawal symptoms. It is converted in the body to its active metabolite nordiazepam (desmethyldiazepam). It is approved and used in several countries for anxiety disorders, epilepsy, and adjunct therapy in acute alcohol withdrawal.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after a single oral dose of 15 mg potassium clorazepate in healthy adult volunteers (mixed sex, age ~18-45 years).</p><h4>References</h4><ol><li><p>Greenblatt, DJ, et al., &amp; Shader, RI (1988). Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. <i>Journal of clinical pharmacology</i> 28(9) 853–859. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1988.tb03228.x&quot;>10.1002/j.1552-4604.1988.tb03228.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2906643/&quot;>https://pubmed.ncbi.nlm.nih.gov/2906643</a></p></li><li><p>Norman, TR, et al., &amp; Maguire, KP (1981). Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: the effect of smoking. <i>European journal of clinical pharmacology</i> 21(3) 229–233. DOI:<a href=&quot;https://doi.org/10.1007/BF00627925&quot;>10.1007/BF00627925</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6119204/&quot;>https://pubmed.ncbi.nlm.nih.gov/6119204</a></p></li><li><p>Hoffman, DJ, &amp; Chun, AH (1975). GLC determination of plasma drug levels after oral administration of clorazepate potassium salts. <i>Journal of pharmaceutical sciences</i> 64(10) 1668–1671. DOI:<a href=&quot;https://doi.org/10.1002/jps.2600641017&quot;>10.1002/jps.2600641017</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/241829/&quot;>https://pubmed.ncbi.nlm.nih.gov/241829</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N05BA05;
